Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata
Journal
Dermatology and therapy
Journal Volume
12
Journal Issue
11
Date Issued
2022-11
Author(s)
Lai, Kun-Wei
Abstract
For decades, contact immunotherapy with dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester has played an important role in both clinical practice and scientific research. It is listed as the first-line treatment for extensive alopecia areata and was more recently approved for melanoma treatment as an orphan drug in the USA. Moreover, owing to the relative low cost and safety, topical immunotherapy has also been used in many infectious, neoplastic, and inflammatory dermatological diseases. It is especially valuable in vulnerable groups, for cosmetic/pain sensitive areas, or for multiple lesions. In this review, we summarize the current evidence supporting the use of contact immunotherapy for treatment of skin diseases, from articles collected from PubMed database. Owing to space limitation and already numerous studies focusing on alopecia areata, we include only skin diseases other than alopecia areata. In addition to diseases that have been reported to be treated by contact immunotherapy, the hypothesized mechanism, prognosis prediction, efficacy, and safety of these topical agents are discussed.
Subjects
Contact immunotherapy
DNCB
DPCP
Dinitrochlorobenzene
Diphencyprone
Diphenylcyclopropenone
SADBE
Squaric acid dibutylester
SDGs
Type
review